Skip to main content
WVE logo

WVE · Wave Life Sciences, Inc. · Metrics

Track WVE — free
$3.70 +0.06 (+1.65%) At close · Sep 30
Market Cap
$744.84M
Shares
197.05M
Volume · Sep 30 4.21M Avg daily vol (3M) 3.05M

WVE metrics

33 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.70
Market cap
$744.84M

Price action

20 metrics
Price change (1W)
-6.3%
Price change (30D)
-25.6%
Price change (3M)
-36.6%
Price change (6M)
-45.8%
Price change (YTD)
-78.2%
Price change (1Y)
-49.5%
Trailing year
Price change (5Y)
-24.5%
52-week high
$21.31
52-week low
$3.64
Change from 52-week high
-82.6%
Change from 52-week low
+1.6%
Annualized volatility
168.4%
Annualized volatility (3M)
55.9%
Beta
1.3
RSI (14D)
24.3
Price vs SMA 50
-26.6%
Price vs SMA 200
-58.0%
Avg volume (3M)
3.05M
Relative volume
1.4
Average dollar volume
$15.80M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
197.05M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
242
13F filer change QoQ
+6
Institutional ownership
93.0%

Short interest

3 metrics
Short interest
9.0%
Latest settlement · 5.2 days to cover
Days to cover
5.2d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$135,072
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1631574 CUSIP 94352A104 13F (30d) 4 filings 4 filers Visit website Investor relations